Platelet Reactivity and Clinical Outcomes After Coronary Artery Implantation of Drug-Eluting Stents in Subjects With Peripheral Arterial Disease: Analysis From the ADAPT-DES Study (Assessment of Dual Antiplatelet Therapy With Drug-Eluting Stents)

Circulation: Cardiovascular Interventions

Volumn 10, Issue 3, 2017, Pages

  Gupta, Rajesh ^a   Kirtane, Ajay J ^b,c   Ozan, M Ozgu ^b   Witzenbichler, Bernhard ^d   Rinaldi, Michael J ^e   Metzger, D Christopher ^f   Weisz, Giora ^b,c,g   Stuckey, Thomas D ^h   Brodie, Bruce R ^h   Mehran, Roxana ^b,i   Ben Yehuda, Ori ^b,c   Stone, Gregg W ^b,c  

^a UNIVERSITY OF TOLEDO MEDICAL CENTER   (United States)

^b CARDIOVASCULAR RESEARCH FOUNDATION   (United States)

^c Department of Medicine   (United States)

^d Helios Amper Klinikum   (Germany)

^e LEVINE CANCER INSTITUTE   (United States)

^f Wellmont CVA Heart Institute   (United States)

^g SHAARE ZEDEK MEDICAL CENTER   (Israel)

^h LeBauer Cardiovasc Res Found M   (United States)

ⁱ MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

coronary artery disease; percutaneous coronary intervention; peripheral arterial disease; stent; thrombosis

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTITHROMBOCYTIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CLOPIDOGREL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; EPTIFIBATIDE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; THIENOPYRIDINE DERIVATIVE; TIROFIBAN; PURINERGIC P2Y RECEPTOR ANTAGONIST; TICLOPIDINE;

ADULT; AGED; ARTICLE; BLEEDING; CARDIOVASCULAR MORTALITY; CLINICAL OUTCOME; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG ELUTING STENT; DUAL ANTIPLATELET THERAPY; FEMALE; FOLLOW UP; HEART DEATH; HEART DISEASE; HEART INFARCTION; HUMAN; IMPLANTATION; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MULTICENTER STUDY; PERCUTANEOUS CORONARY INTERVENTION; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PLATELET REACTIVITY; PRIORITY JOURNAL; PROSPECTIVE STUDY; STENT THROMBOSIS; ANALOGS AND DERIVATIVES; BLOOD; BLOOD CLOTTING PARAMETERS; CHEMICALLY INDUCED; CHI SQUARE DISTRIBUTION; CLINICAL TRIAL; COMBINATION DRUG THERAPY; COMPLICATION; CORONARY ARTERY DISEASE; CORONARY THROMBOSIS; DEVICES; DRUG EFFECTS; KAPLAN MEIER METHOD; MORTALITY; MULTIVARIATE ANALYSIS; MYOCARDIAL INFARCTION; PERIPHERAL ARTERIAL DISEASE; PREDICTIVE VALUE; PROPENSITY SCORE; PROPORTIONAL HAZARDS MODEL; REGISTER; RISK FACTOR; THROMBOCYTE AGGREGATION; TIME FACTOR; TREATMENT OUTCOME;

AGED; ASPIRIN; CHI-SQUARE DISTRIBUTION; CORONARY ARTERY DISEASE; CORONARY THROMBOSIS; DRUG THERAPY, COMBINATION; DRUG-ELUTING STENTS; FEMALE; HEMORRHAGE; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; MYOCARDIAL INFARCTION; PERCUTANEOUS CORONARY INTERVENTION; PERIPHERAL ARTERIAL DISEASE; PLATELET AGGREGATION; PLATELET AGGREGATION INHIBITORS; PLATELET FUNCTION TESTS; PREDICTIVE VALUE OF TESTS; PROPENSITY SCORE; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; PURINERGIC P2Y RECEPTOR ANTAGONISTS; REGISTRIES; RISK FACTORS; TICLOPIDINE; TIME FACTORS; TREATMENT OUTCOME;

EID: 85016074287     PISSN: 19417640     EISSN: 19417632     Source Type: Journal    
DOI: 10.1161/CIRCINTERVENTIONS.116.004904     Document Type: Article

References (24)

1. Ness J, Aronow WS. Prevalence of coexistence of coronary artery disease, ischemic stroke, and peripheral arterial disease in older persons, mean age 80 years, in an academic hospital-based geriatrics practice. J Am Geriatr Soc. 1999;47:1255-1256.
2. Midwall S, Swaminathan RV, Charitakis K, Kim LK, Gordin J, Hriljac I, Minutello RM, Bergman G, Wong SC, Feldman DN. Impact of peripheral vascular disease on short- and long-term outcomes in patients undergoing non-emergent percutaneous coronary intervention in the drug-eluting stent era. J Invasive Cardiol. 2013;25:132-136.
3. Chiu JH, Topol EJ, Whitlow PL, Hsu AP, Tuzcu EM, Franco I, Moliterno DJ. Peripheral vascular disease and one-year mortality following percutaneous coronary revascularization. Am J Cardiol. 2003;92:582-583.
4. Guerrero M, Harjai K, Stone GW, Brodie B, Cox D, Boura J, Grines L, O'Neill W, Grines C. Usefulness of the presence of peripheral vascular disease in predicting mortality in acute myocardial infarction patients treated with primary angioplasty (from the Primary Angioplasty in Myocardial Infarction Database). Am J Cardiol. 2005;96:649-654. doi: 10.1016/j.amjcard.2005.04.037.
5. Jeremias A, Gruberg L, Patel J, Connors G, Brown DL. Effect of peripheral arterial disease on in-hospital outcomes after primary percutaneous coronary intervention for acute myocardial infarction. Am J Cardiol. 2010;105:1268-1271. doi: 10.1016/j.amjcard.2009.12.043.
6. Stone GW, Witzenbichler B, Weisz G, Rinaldi MJ, Neumann FJ, Metzger DC, Henry TD, Cox DA, Duffy PL, Mazzaferri E, Gurbel PA, Xu K, Parise H, Kirtane AJ, Brodie BR, Mehran R, Stuckey TD; ADAPT-DES Investigators. Platelet reactivity and clinical outcomes after coronary artery implantation of drug-eluting stents (ADAPT-DES): a prospective multicentre registry study. Lancet. 2013;382:614-623. doi: 10.1016/S0140-6736(13)61170-8.
7. Cutlip DE, Windecker S, Mehran R, Boam A, Cohen DJ, van Es GA, Steg PG, Morel MA, Mauri L, Vranckx P, McFadden E, Lansky A, Hamon M, Krucoff MW, Serruys PW; Academic Research Consortium. Clinical end points in coronary stent trials: a case for standardized definitions. Circulation. 2007;115:2344-2351. doi: 10.1161/CIRCULATIONAHA.106.685313.
8. Peduzzi P, Concato J, Feinstein AR, Holford TR. Importance of events per independent variable in proportional hazards regression analysis. II. Accuracy and precision of regression estimates. J Clin Epidemiol. 1995;48:1503-1510.
9. Blacher J, Cacoub P, Luizy F, Mourad JJ, Levesque H, Benelbaz J, Michon P, Herrmann MA, Priollet P. Peripheral arterial disease versus other localizations of vascular disease: the ATTEST study. J Vasc Surg. 2006;44:314-318. doi: 10.1016/j.jvs.2006.04.002.
10. Pande RL, Perlstein TS, Beckman JA, Creager MA. Secondary prevention and mortality in peripheral artery disease: National Health and Nutrition Examination Study, 1999 to 2004. Circulation. 2011;124:17-23. doi: 10.1161/CIRCULATIONAHA.110.003954.
11. CAPRIE Steering Committee. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet. 1996;348:1329-1339.
12. Cacoub PP, Bhatt DL, Steg PG, Topol EJ, Creager MA; CHARISMA Investigators. Patients with peripheral arterial disease in the CHARISMA trial. Eur Heart J. 2009;30:192-201. doi: 10.1093/eurheartj/ehn534.
13. Spiliopoulos S, Pastromas G, Katsanos K, Kitrou P, Karnabatidis D, Siablis D. Platelet responsiveness to clopidogrel treatment after peripheral endovascular procedures: the PRECLOP study: clinical impact and optimal cutoff value of on-treatment high platelet reactivity. J Am Coll Cardiol. 2013;61:2428-2434. doi: 10.1016/j.jacc.2013.03.036.
14. Armstrong EJ, Anderson DR, Yeo KK, Singh GD, Bang H, Amsterdam EA, Freischlag JA, Laird JR. Association of dual-antiplatelet therapy with reduced major adverse cardiovascular events in patients with symptomatic peripheral arterial disease. J Vasc Surg. 2015;62:157-165.e1. doi: 10.1016/j.jvs.2015.01.051.
15. Bonaca MP, Bhatt DL, Storey RF, Steg PG, Cohen M, Kuder J, Goodrich E, Nicolau JC, Parkhomenko A, López-Sendón J, Dellborg M, Dalby A, Špinar J, Aylward P, Corbalán R, Abola MT, Jensen EC, Held P, Braunwald E, Sabatine MS. Ticagrelor for prevention of ischemic events after myocardial infarction in patients with peripheral artery disease. J Am Coll Cardiol. 2016;67:2719-2728. doi: 10.1016/j.jacc.2016.03.524.
16. Hiatt WR, Fowkes FG, Heizer G, Berger JS, Baumgartner I, Held P, Katona BG, Mahaffey KW, Norgren L, Jones WS, Blomster J, Millegård M, Reist C, Patel MR; EUCLID Trial Steering Committee and Investigators. Ticagrelor versus clopidogrel in symptomatic peripheral artery disease. N Engl J Med. 2017;376:32-40. doi: 10.1056/NEJMoa1611688.
17. Bonaca MP, Scirica BM, Creager MA, Olin J, Bounameaux H, Dellborg M, Lamp JM, Murphy SA, Braunwald E, Morrow DA. Vorapaxar in patients with peripheral artery disease: results from TRA2°PTIMI 50. Circulation. 2013;127:1522-1529, 1529.e1. doi: 10.1161/CIRCULATIONAHA.112.000679.
18. Bonaca MP, Gutierrez JA, Creager MA, Scirica BM, Olin J, Murphy SA, Braunwald E, Morrow DA. Acute limb ischemia and outcomes with vorapaxar in patients with peripheral artery disease: results from the trial to assess the effects of vorapaxar in preventing heart attack and stroke in patients with atherosclerosis-thrombolysis in myocardial infarction 50 (TRA2°P-TIMI 50). Circulation. 2016;133:997-1005. doi: 10.1161/CIRCULATIONAHA.115.019355.
19. Price MJ, Berger PB, Teirstein PS, Tanguay JF, Angiolillo DJ, Spriggs D, Puri S, Robbins M, Garratt KN, Bertrand OF, Stillabower ME, Stillablower ME, Aragon JR, Kandzari DE, Stinis CT, Lee MS, Manoukian SV, Cannon CP, Schork NJ, Topol EJ; GRAVITAS Investigators. Standardvs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: the GRAVITAS randomized trial. JAMA. 2011;305:1097-1105. doi: 10.1001/jama.2011.290.
20. Collet JP, Cuisset T, Rangé G, Cayla G, Elhadad S, Pouillot C, Henry P, Motreff P, Carrié D, Boueri Z, Belle L, Van Belle E, Rousseau H, Aubry P, Monségu J, Sabouret P, O'Connor SA, Abtan J, Kerneis M, Saint-Etienne C, Barthélémy O, Beygui F, Silvain J, Vicaut E, Montalescot G; ARCTIC Investigators. Bedside monitoring to adjust antiplatelet therapy for coronary stenting. N Engl J Med. 2012;367:2100-2109. doi: 10.1056/NEJMoa1209979.
21. Trenk D, Stone GW, Gawaz M, Kastrati A, Angiolillo DJ, Müller U, Richardt G, Jakubowski JA, Neumann FJ. A randomized trial of prasugrel versus clopidogrel in patients with high platelet reactivity on clopidogrel after elective percutaneous coronary intervention with implantation of drug-eluting stents: results of the TRIGGER-PCI (Testing Platelet Reactivity in Patients Undergoing Elective Stent Placement on Clopidogrel to Guide Alternative Therapy With Prasugrel) study. J Am Coll Cardiol. 2012;59:2159-2164. doi: 10.1016/j.jacc.2012.02.026.
22. Gurbel PA, Erlinge D, Ohman EM, Neely B, Neely M, Goodman SG, Huber K, Chan MY, Cornel JH, Brown E, Zhou C, Jakubowski JA, White HD, Fox KA, Prabhakaran D, Armstrong PW, Tantry US, Roe MT; TRILOGY ACS Platelet Function Substudy Investigators. Platelet function during extended prasugrel and clopidogrel therapy for patients with ACS treated without revascularization: the TRILOGY ACS platelet function substudy. JAMA. 2012;308:1785-1794. doi: 10.1001/jama.2012.17312.
23. Wiviott SD, Braunwald E, McCabe CH, Montalescot G, Ruzyllo W, Gottlieb S, Neumann FJ, Ardissino D, De Servi S, Murphy SA, Riesmeyer J, Weerakkody G, Gibson CM, Antman EM; TRITON-TIMI 38 Investigators. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2007;357:2001-2015. doi: 10.1056/NEJMoa0706482.
24. Wallentin L, Becker RC, Budaj A, Cannon CP, Emanuelsson H, Held C, Horrow J, Husted S, James S, Katus H, Mahaffey KW, Scirica BM, Skene A, Steg PG, Storey RF, Harrington RA, Freij A, Thorsén M; PLATO Investigators. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2009;361:1045-1057. doi: 10.1056/NEJMoa0904327.